FLGTMEDIUM SIGNALFINANCIAL10-K

FLGT shows mixed financial performance with growing revenues offset by deepening losses and increased regulatory scrutiny.

The company appears to be investing heavily in growth while facing mounting regulatory challenges, as evidenced by removal of language about voluntary disclosure processes with regulatory agencies. The substantial increase in current assets alongside growing losses suggests FLGT is burning through capital to fund expansion, which may pressure future financing needs.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

FLGT demonstrated solid operational momentum with gross profit growing 22.1% to $130.9M and current assets expanding substantially to $550.5M, indicating strong cash generation or recent financing activity. However, profitability metrics deteriorated meaningfully, with net losses widening to $60.5M and operating losses expanding to $91.1M. The company appears to be prioritizing growth investments over near-term profitability, evidenced by continued R&D spending growth of 10.4% and reduced capital expenditures, suggesting a shift toward operational scaling rather than infrastructure buildout.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+55.7%
$353.6M→$550.5M

Current assets grew 55.7% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-44%
$40.3M→$22.6M

Capex reduced 44% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
-41.7%
-$42.7M→-$60.5M

Net income declined 41.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-23.2%
-$73.9M→-$91.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Accounts Receivable
Balance Sheet
+22.8%
$69.0M→$84.8M

Receivables grew 22.8% — monitor days sales outstanding for collection efficiency.

Gross Profit
P&L
+22.1%
$107.2M→$130.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Liabilities
Balance Sheet
+17.6%
$90.8M→$106.8M

Liabilities increased 17.6% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+16.6%
$72.9M→$85.0M

Current liabilities rose 16.6% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
+10.4%
$48.8M→$53.9M

R&D investment increased 10.4% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 23, 2026, there were 31,230,632 outstanding shares of the registrant s common stock.
and foreign laws and regulations applicable to our business, and our ability to comply with these regulations; our ability to effectively respond to the results of payor audits and government audits and investigations, such as our currently ongoing U.S.
Department of Health Resources and Services Administration, or HRSA, audit and Civil Investigative Demands, or CIDs; our ability to prevent errors in interpreting the results of our tests so as to avoid product liability and professional liability claims; our ability to obtain and maintain coverage and adequate reimbursement for our tests and to manage the complexity of billing and collecting such reimbursement; our beliefs that our tests marketed in the United States are, and will continue to be, laboratory developed tests; changes to the state of the U.S.
and foreign healthcare markets, including the role of governments in the healthcare industry, and the impact of general uncertainty in the U.S.
We have also made significant investment in digital pathology using artificial intelligence, or AI, technology, which allows us to digitize specimen slides instead of the traditional method of microscopy.
+7 more — sign up free →
REMOVED
For purposes of this calculation, it has been assumed that all shares of the registrant s common stock held by directors, executive officers and persons beneficially owning 5% or more of the registrant s common stock are held by affiliates; however, the treatment of these persons as affiliates for purposes of this calculation is not, and shall not be considered, a determination as to whether such persons are affiliates of the registrant for any other purpose.
As of February 24, 2025 , there were 30,829,454 outstanding shares of the registrant s common stock.
and foreign laws and regulations applicable to our business, and our ability to comply with these regulations, and the results or potential liability associated with disclosure pursuant to any voluntary disclosure process by and between us and applicable regulatory agencies and bodies; our ability to effectively respond to the results of payor audits and government audits and investigations, such as our currently ongoing U.S.
Department of Health Resources and Services Administration, or HRSA, audit and Civil Investigative Demands, or CIDs; our ability to prevent errors in interpreting the results of our tests so as to avoid product liability and professional liability claims; our ability to obtain and maintain coverage and adequate reimbursement for our tests and to manage the complexity of billing and collecting such reimbursement; the state of the U.S.
and foreign healthcare markets, including the role of governments in the healthcare industry, generally, pressures or incentives to reduce healthcare costs while expanding individual benefits, and the impact of general uncertainty in the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →